By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


SEARCH JOBS

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.


Key Statistics


Email: Info@junotherapeutics.com
Ownership: Private

Web Site: Juno Therapeutics
Employees: n/a
Symbol: 
 



Industry
Biotechnology






Company News
Amazon.com (AMZN)-Backed Juno Therapeutics Aims Even Higher; Eyes $212 Million IPO 12/16/2014 3:18:02 PM
Lucky Juno Therapeutics Sets Terms For Biggest IPO Of 2014: $191 Million 12/9/2014 3:37:43 PM
Juno Therapeutics’s CAR T and TCR Investigational Product Candidates Demonstrate Promising Outcomes In Clinical Trials In Patients With B-Cell Cancers 12/9/2014 12:44:07 PM
Juno Therapeutics Executes License For Phase I CAR T Product Candidate Targeting CD22 For Hematological Malignancies 12/5/2014 9:11:15 AM
Juno Therapeutics Appoints Jeffrey Bluestone As Scientific Advisor 12/2/2014 1:07:54 PM
Juno Therapeutics Appoints Maggie Wilderotter To Board Of Directors 11/25/2014 9:25:33 AM
Juno Therapeutics T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 11/24/2014 9:46:19 AM
Juno Therapeutics's JCAR015 Leukemia T Cell Therapy Granted Orphan Drug Designation By FDA 11/18/2014 11:44:47 AM
Juno Therapeutics Files For IPO 11/17/2014 8:04:01 AM
Top 30 Life Science Startups To Watch In The U.S. 10/23/2014 4:27:21 AM
123
//-->